“ Current pipeline of gene therapies for common diseases spans three major therapeutics areas: ophthalmology, metabolic disease and neurology “ “ Company to host symposium on Advancing Gene...
Kriya anticipates up to 5 programs to enter clinic by the end of 2025 Current pipeline of gene therapies for common diseases spans three major therapeutics areas: ophthalmology, metabolic...
Kriya Announces Gene Therapy Program for Thyroid Eye Disease
“ Everads' next generation suprachoroidal delivery technology enables targeted drug delivery to the retina, which Kriya intends to use for multiple ophthalmology gene therapy product candidates “ ...
“ Kriya envisions treating people with NASH using a one-time intramuscular gene therapy enabling continuous expression of native FGF21 “ “ Kriya anticipates advancing its NASH gene therapy candidate...
“ Kriya's therapeutic pipeline addresses a broad range of diseases that collectively affect millions of patients worldwide”with a goal of delivering transformational clinical benefits with one-time...
PALO ALTO, Calif. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Kriya Therapeutics, Inc., a biopharmaceutical company developing gene therapies for conditions affecting millions of people around the world, today announced that it will present 10 abstracts at the 26th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) taking place in Los Angeles, CA, May 16-20, 2023.
Gene therapy biotech Kriya Therapeutics is continuing its acquisition streak to build out a pipeline, this time with a focus on the brain.